טוען...
Oncologists’ Barriers and Facilitators for Oncotype DX Use: Qualitative Study
BACKGROUND: Oncotype DX (ODX), a tumor gene profiling test, has been incorporated into clinical guidelines to aid in adjuvant chemotherapy decision-making for early-stage, hormone receptor positive breast cancer patients. Despite US guidelines, less than half of eligible women receive testing. Reaso...
שמור ב:
| הוצא לאור ב: | Int J Technol Assess Health Care |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6526532/ https://ncbi.nlm.nih.gov/pubmed/27958190 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1017/S026646231600060X |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|